Showing 1 - 10 of 21,761
equilibrium. . In particular, by comparing the prosecuted and non-prosecuted open Isapres before and during the collusive period …, we show that sales efforts of the accused Isapres were reduced during the transition period toward lower-quality plans …, that the profitability of the two groups of Isapres increased, and that the rate of transfers within the group of accused …
Persistent link: https://www.econbiz.de/10005808238
In September 2005, the Chilean Competition Authority filed a lawsuit against the 5 largest private health insurance providers for violation of antitrust laws, specifically accusing them of collusion in the coverage of the plans offered to consumers between March 2002 and March 2003. In fact,...
Persistent link: https://www.econbiz.de/10012720548
The purpose of this paper is to make transparent what Medco does not. Transparency in a company's business model is good for economic welfare (i.e., competition) but not necessarily good for a company's stock performance. This paper is written from the perspective of economic welfare, not from...
Persistent link: https://www.econbiz.de/10012981561
A statistical comparison of the business models of Express Scripts and Medco is presented. While both have similar rebates retention rates, Medco extracts significantly higher rebates per prescription. The source of the difference is due to different approaches to formulary compliance, rather...
Persistent link: https://www.econbiz.de/10012981562
On September 6, 2005, the Federal Trade Commission (FTC) released a long awaited study of potential conflicts of interest by independent pharmacy benefit managers (PBMs). Like any good study of alleged wrongdoing, the FTC examined both motive and performance.The FTC's analysis indicated that it...
Persistent link: https://www.econbiz.de/10012981787
The purpose of this paper is to estimate the rebate-retention rate of pharmacy benefit managers (PBMs). The rebate-retention rate is the ratio of net rebates retained to gross rebates received from drug manufacturers. What isn’t retained is passed on to health care plan sponsors. A different...
Persistent link: https://www.econbiz.de/10014124975
Se estudian los problemas de seleccio?n adversa y riesgo moral dentro del mercado de aseguramiento en salud, con el fin de determinar cua?l ha sido el rol de las cuotas moderadoras en el uso de servicios y verificar la hipo?tesis existente sobre la concentracio?n de la poblacio?n ma?s riesgosa...
Persistent link: https://www.econbiz.de/10011255392
El trabajo analiza el efecto de la introducción de un plan mínimo obligatorio de prestaciones (PMO) que tanto el seguro público como los seguros privados deben cubrir. El análisis se realiza considerando la existencia de un mercado de seguros de salud segmentado en el sentido que, previo a...
Persistent link: https://www.econbiz.de/10005808246
Se analiza el efecto de la introducción de un plan mínimo obligatorio de prestaciones (PMO) en un mercado de seguros de salud segmentado en que el seguro público y las aseguradoras privadas atienden respectivamente a riesgos altos y bajos (la segmentación es obtenida de manera endógena en...
Persistent link: https://www.econbiz.de/10008542845
Patent holders attempt to mitigate the loss of monopoly power by authorizing generic entry prior to patent expiry (early entry). Off-patent competition may be adversely affected if early entry substantially lowers the attractiveness of subsequent generic entry. This study assesses the impact of...
Persistent link: https://www.econbiz.de/10010333899